GW Hunninghake, S Gilbert, R Pueringer, C Dayton, C Floerchinger, R Helmers, R Merchant, J Wilson, J Galvin and D Schwartz
Department of Internal Medicine, Veterans Affairs Medical Center, Iowa City, Iowa.

The clinical characteristics and pathology of sarcoidosis are well defined; however, the optimal therapy for this disorder remains unclear. Although patients respond, acutely, to corticosteroid therapy, it is not clear that these agents ultimately alter the natural history of this disease. These observations and that corticosteroids have significant side effects suggest that only patients who will clearly benefit from corticosteroid therapy should be treated. In a prospective study of patients' with sarcoidosis (n = 98), we limited our use of corticosteroids to those patients who had objective evidence of recent deterioration in lung function or serious extrapulmonary disease. All patients with sarcoidosis fulfilling these criteria were treated with corticosteroids. Patients were tapered off corticosteroids after they were treated for 1 yr. Of the 98 study subjects, 91 had not received therapy for the disease and 7 were on therapy before entry into the study. Of the 91 previously untreated patients, 55 were observed without therapy and 36 were treated with corticosteroids. Of those who were observed off therapy, only eight deteriorated. Of these latter patients, six responded and stabilized with the administration of corticosteroids for treatment of the underlying disease, to antibiotics for an associated bronchiectasis, or to diuretics for treatment for congestive heart failure; two were lost to follow-up. None of these six patients deteriorated while receiving corticosteroids. Of the 36 patients who deteriorated and were treated with corticosteroids, 20 remained stable and 16 improved clinically. Of the 37 patients who were eventually tapered off corticosteroids, five deteriorated and required reinitiation of corticosteroid therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				S. W Dubrey, A. Bell, and T. K Mittal Sarcoid heart disease Postgrad. Med. J., October 1, 2007; 83(984): 618 - 623. [Abstract] [Full Text] [PDF]

				Y. S. Wasfi, C. S. Rose, J. R. Murphy, L. J. Silveira, J. C. Grutters, Y. Inoue, M. A. Judson, and L. A. Maier A New Tool To Assess Sarcoidosis Severity Chest, May 1, 2006; 129(5): 1234 - 1245. [Abstract] [Full Text] [PDF]

				R.P. Baughman, M.A. Judson, A. Teirstein, H. Yeager, M. Rossman, G.L. Knatterud, B. Thompson, and for the ACCESS research team Presenting characteristics as predictors of duration of treatment in sarcoidosis QJM, May 1, 2006; 99(5): 307 - 315. [Abstract] [Full Text] [PDF]

				P. Chevalet, R. Clement, O. Rodat, A. Moreau, J.-M. Brisseau, and J.-P. Clarke Sarcoidosis Diagnosed in Elderly Subjects: Retrospective Study of 30 Cases Chest, November 1, 2004; 126(5): 1423 - 1430. [Abstract] [Full Text] [PDF]

				W. J. Martin II, M. C. Iannuzzi, D. B. Gail, and H. H. Peavy Future Directions in Sarcoidosis Research: Summary of an NHLBI Working Group Am. J. Respir. Crit. Care Med., September 1, 2004; 170(5): 567 - 571. [Abstract] [Full Text] [PDF]

				C. E. Cox, J. F. Donohue, C. D. Brown, Y. P. Kataria, and M. A. Judson Health-Related Quality of Life of Persons With Sarcoidosis Chest, March 1, 2004; 125(3): 997 - 1004. [Abstract] [Full Text] [PDF]

				K. W. Thomas and G. W. Hunninghake Sarcoidosis JAMA, June 25, 2003; 289(24): 3300 - 3303. [Full Text] [PDF]

				P. D. W. Kiely, C. W. Heron, and F. E. Bruckner Presentation and management of idiopathic inflammatory muscle disease: four case reports and commentary from a series of 78 patients Rheumatology, April 1, 2003; 42(4): 575 - 582. [Full Text] [PDF]

				M.W. Ziegenhagen, M.E. Rothe, M. Schlaak, and J. Muller-Quernheim Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis Eur. Respir. J., March 1, 2003; 21(3): 407 - 413. [Abstract] [Full Text] [PDF]

				A. Pietinalho, P. Tukiainen, T. Haahtela, T. Persson, and O. Selroos Early Treatment of Stage II Sarcoidosis Improves 5-Year Pulmonary Function Chest, January 1, 2002; 121(1): 24 - 31. [Abstract] [Full Text] [PDF]

				R. P. BAUGHMAN, A. S. TEIRSTEIN, M. A. JUDSON, M. D. ROSSMAN, H. YEAGER JR., E. A. BRESNITZ, L. DEPALO, G. HUNNINGHAKE, M. C. IANNUZZI, C. J. JOHNS, et al. Clinical Characteristics of Patients in a Case Control Study of Sarcoidosis Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1885 - 1889. [Abstract] [Full Text] [PDF]

				L. S. Efferen The Challenge of Sarcoidosis Chest, September 1, 2001; 120(3): 697 - 699. [Full Text] [PDF]

				U. Costabel Sarcoidosis: clinical update Eur. Respir. J., July 1, 2001; 18(32_suppl): 56S - 68s. [Abstract] [Full Text] [PDF]

				A ROTHOVA Ocular involvement in sarcoidosis Br. J. Ophthalmol., January 1, 2000; 84(1): 110 - 116. [Full Text]

				A. Pietinalho, P. Tukiainen, T. Haahtela, T. Persson, and O. Selroos Oral Prednisolone Followed by Inhaled Budesonide in Newly Diagnosed Pulmonary Sarcoidosis: A Double-Blind, Placebo-Controlled Multicenter Study Chest, August 1, 1999; 116(2): 424 - 431. [Abstract] [Full Text] [PDF]

				G. Hunninghake Statement on Sarcoidosis Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 736 - 755. [Full Text]

				R. P Baughman and E. E Lower A clinical approach to the use of methotrexate for sarcoidosis Thorax, August 1, 1999; 54(8): 742 - 746. [Full Text]

				D. M Mitchell and A. Woodcock Introduction Thorax, August 1, 1999; 54(90002): S1 - 1. [PDF]

				M. BALTZAN, S. MEHTA, T. H. KIRKHAM, and M. G. COSIO Randomized Trial of Prolonged Chloroquine Therapy in Advanced Pulmonary Sarcoidosis Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 192 - 197. [Abstract] [Full Text]

				M. A. Judson An Approach to the Treatment of Pulmonary Sarcoidosis With Corticosteroids: The Six Phases of Treatment Chest, April 1, 1999; 115(4): 1158 - 1165. [Abstract] [Full Text] [PDF]

				O. P. Sharma Effectiveness of Chloroquine and Hydroxychloroquine in Treating Selected Patients With Sarcoidosis With Neurological Involvement Arch Neurol, September 1, 1998; 55(9): 1248 - 1254. [Abstract] [Full Text] [PDF]

				G. W. Hunninghake Goal of the Treatment for Sarcoidosis . Minimize Harm for the Patient Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1369 - 1370. [Full Text]

				C. P. WYSER, E. M. van SCHALKWYK, B. ALHEIT, P. G. BARDIN, and J. R. JOUBERT Treatment of Progressive Pulmonary Sarcoidosis with Cyclosporin A . A Randomized Controlled Trial Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1371 - 1376. [Abstract] [Full Text]

				M. W. ZIEGENHAGEN, U. K. BENNER, G. ZISSEL, P. ZABEL, M. SCHLAAK, and J. MÜLLER-QUERNHEIM Sarcoidosis: TNF-alpha Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1586 - 1592. [Abstract] [Full Text]

				L. S. Newman, C. S. Rose, and L. A. Maier Sarcoidosis N. Engl. J. Med., April 24, 1997; 336(17): 1224 - 1234. [Full Text] [PDF]

				B. T. SOCIETY and S. O. C. COMMITTEE The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations Thorax, April 1, 1990; 54(90001): 1S - 28. [Full Text]